title: Effect of cholecystokinin1 receptor antagonist loxiglumide (CR1505) on basal pancreatic exocrine secretion in conscious rats.
abstract: OBJECTIVE
  To examine the involvement of cholecystokinin (CCK) in the basal pancreatic exocrine, we investigated the effect of loxiglumide (CR1505), a CCK1 receptor antagonist, on basal pancreatic exocrine secretion in conscious rats.
  
  
  METHODS
  After the basal collection of pancreatic juice for 1 hour, loxiglumide (10 mg/kg/h) or saline was infused via the femoral vein continuously for 2 hours.
  
  
  RESULTS
  Loxiglumide significantly suppressed the basal pancreatic protein and amylase outputs. However, loxiglumide did not alter the basal pancreatic juice volume.
  
  
  CONCLUSIONS
  These results demonstrate that loxiglumide suppresses basal pancreatic exocrine secretion in normal rats. They also suggest that CCK is involved in basal pancreatic exocrine in conscious rats and that loxiglumide may be useful as a therapeutic agent for pancreatitis, even during fasting, by attenuating the basal pancreatic exocrine burden on the pancreas.
authors.affiliation: Research Laboratory IV, Pharmaceutical Research Division, Mitsubishi Pharma Corporation, Kanagawa, Japan. Ishizaki.Kaoru@mh.m-pharma.co.jp
authors.forename: Kaoru
authors.initials: K
authors.lastname: Ishizaki
authors.forename: Shigemasa
authors.initials: S
authors.lastname: Kinbara
authors.forename: Makoto
authors.initials: M
authors.lastname: Kawamura
authors.forename: Kunio
authors.initials: K
authors.lastname: Kimura
authors.forename: Keiko
authors.initials: K
authors.lastname: Shiratori
authors.forename: Tadashi
authors.initials: T
authors.lastname: Takeuchi
mesh_terms: D000681:Amylases / Q000378:metabolism; D000818:Animals; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D007262:Infusions, Intravenous; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D010189:Pancreatic Juice / Q000378:metabolism; D011377:Proglumide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D011506:Proteins / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors* / Q000502:physiology; D014851:Wakefulness
chemical_list: D006727:Hormone Antagonists; D011506:Proteins; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; C053737:loxiglumide; D000681:Amylases; D011377:Proglumide